Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
GYRE
Stock Latest News
Company Announcements
Gyre Therapeutics Files NDA in China for F351
6d ago
8K
GYRE
Premium
Ratings
Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval
12d ago
GYRE
Premium
The Fly
Gyre Therapeutics’ liver fibrosis candidate granted priority review in China
12d ago
GYRE
Premium
Company Announcements
Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions
14d ago
GYRE
Premium
Company Announcements
Gyre Therapeutics Projects Strong Growth for Fibrosis Programs
17d ago
8K
GYRE
Premium
The Fly
Gyre Therapeutics reports Q4 EPS (2c), consensus 1c
17d ago
GYRE
Premium
The Fly
Gyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M
17d ago
GYRE
Premium
Company Announcements
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger
27d ago
8K
GYRE
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
27d ago
GYRE
PULM
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
27d ago
GYRE
PULM
Premium
The Fly
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
27d ago
GYRE
PULM
Premium
Ratings
Regulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
3M ago
GYRE
Premium
Company Announcements
Gyre Therapeutics Advances Hydronidone Toward China Approval
3M ago
8K
GYRE
Premium
The Fly
Gyre Therapeutics announces alignment with China’s CDE on hydronidone
3M ago
GYRE
Premium
Company Announcements
Gyre Therapeutics Reports Strong Q3 2025 Results
5M ago
GYRE
Premium
Ratings
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
5M ago
GYRE
Premium
The Fly
Gyre Therapeutics cuts FY25 revenue view to $115M-$118M from $118M-$128M
5M ago
GYRE
Premium
The Fly
Gyre Therapeutics reports Q3 EPS 3c, consensus (2c)
5M ago
GYRE
Premium
Ratings
Buy Rating for Gyre Therapeutics Driven by Phase 3 Trial Progress and Strategic Asset Valuation
5M ago
GYRE
Premium
The Fly
Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules
6M ago
GYRE
Premium
The Fly
Gyre Therapeutics initiated with a Buy at Jefferies
6M ago
GYRE
Premium
Company Announcements
Gyre Therapeutics Announces Positive Phase 3 Results
7M ago
8K
GYRE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
